Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall tone reveals a keen interest in less invasive screening methods like blood and stool tests, with posts citing data about their benefits and limitations. Many emphasize that while these new tests could significantly reduce colorectal cancer incidence and mortality, they are still less impactful than colonoscopy, as shown by phrases such as 'less profoundly effective' and 'still recommends colonoscopy.' The tone and choice of words suggest an acknowledgment of the potential impact of these innovations but also stress the importance of traditional methods for thorough detection.
Most discussions acknowledge the potential benefits of novel molecular tests but emphasize that they are less effective than traditional colonoscopy.
Participants show high interest in new screening options, often highlighting their less invasive nature and potential to increase screening rates.
The posts reference specific findings from the study, citing comparisons between testing methods and discussing clinical implications.
The discussions recognize that the adoption of these tests could influence screening practices, though emphasizing that colonoscopy remains the gold standard.
ICYMI: First-generation novel cell free blood DNA (cf-bDNA) tests have the potential to meaningfully decrease the incidence and mortality of CRC compared with no screening, but substantially less profoundly than colonoscopy or stool tests. https://t.co/V507lZuRA3 @StanfordMed https://t.co/wpsmFuj9XC
SCI member Uri Ladabaum & others found that 1st gen novel cf-bDNA tests may potentially < the incidence and mortality of #ColorectalCancer compared with no screening, but substantially less profoundly than screening #colonoscopy or stool tests. https://t.co/1zlEGimrF7 https://t.co/Z5mqNxcL6B
From the Annals ‘Spotlight on 2024’ collection: First-gen novel cell free blood DNA tests could decrease the incidence and mortality of CRC compared with no screening, but substantially less profoundly than colonoscopy or stool tests. https://t.co/R9aX4ZnC78 @StanfordMed https://t.co/wnlBYNKgiR
New: First-generation novel cell free blood DNA (cf-bDNA) tests have the potential to meaningfully decrease the incidence and mortality of CRC compared with no screening, but substantially less profoundly than colonoscopy or stool tests. https://t.co/V507lZuRA3 @StanfordMed https://t.co/SItkPMeqVD
ICYMI: Don’t skip the colonoscopy. First-gen novel cell free blood DNA tests have the potential to decrease the incidence and mortality of CRC compared with no screening, but substantially less profoundly than colonoscopy or stool tests. https://t.co/V507lZuRA3 @StanfordMed https://t.co/jdNElqgssr
From the Annals ‘Spotlight on 2024’ collection: First-gen novel cell free blood DNA tests could decrease the incidence and mortality of CRC compared with no screening, but substantially less profoundly than colonoscopy or stool tests: https://t.co/HaIg02lCLU @StanfordMed https://t.co/vTkR7LgSIy
Andrew Barnell discusses innovative CRC screening methods using RNA biomarkers from stool samples. The FDA-approved ColoSense test offers a noninvasive alternative to colonoscopy, highlighting the importance of…
https://t.co/4O4JQnKwM7 This study reiterates cell-free blood-based DNA screening tests for CRC should only be offered who declined colonoscopy/ and stool testing. @ESGE_news @my_ueg @ASGEendoscopy @BritSocGastro #GITwitter
From the Annals ‘Spotlight on 2024’ collection: First-gen novel cell free blood DNA tests could decrease the incidence and mortality of CRC compared with no screening, but substantially less profoundly than colonoscopy or stool tests: https://t.co/HaIg02lCLU @StanfordMed https://t.co/vTkR7LgSIy
From the Annals ‘Spotlight on 2024’ collection: First-gen novel cell free blood DNA tests could decrease the incidence and mortality of CRC compared with no screening, but substantially less profoundly than colonoscopy or stool tests. https://t.co/R9aX4ZnC78 @StanfordMed https://t.co/wnlBYNKgiR
New less-invasive screening options, like stool-based and blood-based DNA tests, are gaining attention. However, a recent study confirms that colonoscopies remain the most effective tool for early detection. https://t.co/pEpvGiPd7z https://t.co/Ez3Mc7JNtx
https://t.co/vKvSNnOkRg
Impacto proyectado y rentabilidad de las nuevas pruebas de cribado moleculares de sangre o de heces para cáncer colorrectal https://t.co/qrc2IusMDY PMID 39467291
RT @AnnalsofIM: ICYMI: First-generation novel cell free blood DNA (cf-bDNA) tests have the potential to meaningfully decrease the incidence…
RT @AnnalsofIM: ICYMI: First-generation novel cell free blood DNA (cf-bDNA) tests have the potential to meaningfully decrease the incidence…
ICYMI: First-generation novel cell free blood DNA (cf-bDNA) tests have the potential to meaningfully decrease the incidence and mortality of CRC compared with no screening, but substantially less profoundly than colonoscopy or stool tests. https://t.co/V507lZuRA3 @StanfordMed https://t.co/wpsmFuj9XC
Projected Impact and Cost-Effectiveness of Novel Molecular Blood-Based or Stool-Based Screening Tests for Colorectal Cancer https://t.co/EzDuAywNj4
SCI member Uri Ladabaum & others found that 1st gen novel cf-bDNA tests may potentially < the incidence and mortality of #ColorectalCancer compared with no screening, but substantially less profoundly than screening #colonoscopy or stool tests. https://t.co/1zlEGimrF7 https://t.co/Z5mqNxcL6B
RT @AnnalsofIM: ICYMI: Don’t skip the colonoscopy. First-gen novel cell free blood DNA tests have the potential to decrease the incidence a…
ICYMI: Don’t skip the colonoscopy. First-gen novel cell free blood DNA tests have the potential to decrease the incidence and mortality of CRC compared with no screening, but substantially less profoundly than colonoscopy or stool tests. https://t.co/V507lZuRA3 @StanfordMed https://t.co/jdNElqgssr
RT @AnnalsofIM: New: First-generation novel cell free blood DNA (cf-bDNA) tests have the potential to meaningfully decrease the incidence a…
本日のおすすめ記事（消化器内科） https://t.co/1vLhILCylG
New: First-generation novel cell free blood DNA (cf-bDNA) tests have the potential to meaningfully decrease the incidence and mortality of CRC compared with no screening, but substantially less profoundly than colonoscopy or stool tests. https://t.co/V507lZuRA3 @StanfordMed https://t.co/SItkPMeqVD